Search Result
Results for "
Staphylococcus aureus (MRSA)
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-N6908
-
|
|
Bacterial
|
Infection
Inflammation/Immunology
Cancer
|
|
Continentalic acid from Aralia continentalis has minimum inhibitory concentrations (MICs) of approximately 8-16 µg/mL against S. aureus, including the Methicillin (HY-121544) susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus (MRSA) standard strains .
|
-
-
- HY-115965
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
VP-4604 is a potent anti-methicillin-resistant Staphylococcus aureus (MRSA) agent. VP-4604 exhibits significant microbial growth inhibition toward Staphylococcus aureus (ATCC 43300) with MIC of 4-8 µg/mL. VP-4604 inhibits the growth of methicillin‐resistant Staphylococcus aureus with growth inhibition >95% .
|
-
-
- HY-163528
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 213 (compound Thy3d) shows potent antimicrobial activity by disrupting the integrity of
the membrane of bacterial, with the MIC of 0.5 μg/ml for Staphylococcus aureus (MRSA) .
|
-
-
- HY-161823
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 13 (Compound 9b) is an agent against methicillin-resistant Staphylococcus aureus (MRSA), exhibiting a minimum inhibitory concentration (MIC) of 0.5–2 μg/mL against clinically isolated MRSA strains. Anti-MRSA agent 13 possesses favorable biosafety, plasma tolerance stability, and a low tendency to develop resistance. Anti-MRSA agent 13 disrupts cell walls and membranes, reduces metabolic activity, causes oxidative damage, affects DNA function, and ultimately leads to MRSA death through multi-target synergies .
|
-
-
- HY-163716
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 222 ((R)-O30 (5)) is a antimicrobial agent that inhibits methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
-
- HY-170847
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 24 (compound 6K) is an antimicrobial agent that targets Staphylococcus aureus (MRSA), especially penicillin-resistant Staphylococcus aureus .
|
-
-
- HY-N3789
-
|
|
Bacterial
|
Infection
|
|
Dunnianol is a natural sesqui-neoligan with moderate antibacterial activity. Dunnianol inhibits Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA).
|
-
-
- HY-174985
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 32 (Compound 26) is an orally active and selective SaClpP (Staphylococcus aureus ClpP protease) activator with an EC50 value of 0.98 μM. Anti-MRSA agent 32 activates SaClpP to abnormally degrade bacterial proteins, inhibiting the proliferation of Staphylococcus aureus. Anti-MRSA agent 32 promotes wound healing in a murine skin infection model. Anti-MRSA agent 32 is promising for research of infectious diseases such as methicillin-resistant Staphylococcus aureus (MRSA) infections .
|
-
-
- HY-142124
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Kalimantacin A is a potent antibiotic. Kalimantacin A shows antibacterial activity against staphylococcus including methicillin-resistant staphylococcus aureus (MRSA) .
|
-
-
- HY-163906
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 16 (Compound 4) is an inhibitor of methicillin-resistant Staphylococcus aureus (MRSA). Anti-MRSA agent 16 is effective in combination with oxacillin or meropenem in infected mice .
|
-
-
- HY-115964
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
VP-4556 is a potent anti-methicillin-resistant Staphylococcus aureus (MRSA) agent. VP-4556 exhibits significant microbial growth inhibition toward Staphylococcus aureus (ATCC 43300) with MIC of 8 µg/mL. VP-4556 inhibits the growth of methicillin‐resistant Staphylococcus aureus with growth inhibition >95% .
|
-
-
- HY-17626B
-
|
WCK-2349 hydrochloride
|
Antibiotic
|
Infection
|
|
Alalevonadifloxacin (hydrochloride) (WCK-2349 (hydrochloride)) is a oraaly active anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotic .
|
-
-
- HY-N8186
-
|
|
Bacterial
|
Infection
|
|
(3R)-7,4’-Dihydrohomoisoflavanone is a natural product with antibacterial activities against S. aureus and methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
-
- HY-N14125
-
|
|
Bacterial
|
Infection
|
|
Chloroquinocin has moderate activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
-
- HY-163073
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 9 (compound 39) shows antibacterial effects against clinically isolated methicillin-resistant Staphylococcus aureus (MRSA) with MIC values of 1 μg/ml. Anti-MRSA agent 9 also shows anti-MRSA efficacy in vivo .
|
-
-
- HY-172912
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 27 (compound 4a) is a potent anti-methicillin-resistant Staphylococcus aureus agent with a MIC of 0.0975 μmol/L. Anti-MRSA agent 27 disrupts MRSA biofilms and suppresses hemolytic toxin production .
|
-
-
- HY-157482
-
|
|
Bacterial
|
Infection
|
|
EBP-59 is a bacterial inhibitor with antibiofilm activity against Gram-positive bacteria. EBP-59 is effective against Staphylococcus aureus and MRSA (methicillin–resistant staphylococcus aureus). EBP-59 can be used to study bacterial infections .
|
-
-
- HY-161803
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Anti-MRSA agent 12 (Compound SM-5) is an antibiotic, which exhibits antibacterial activity against Staphylococcus aureus, S. epidermidis and Escherichia coli with MIC of 7.81, 7.81 and 62.5 μM. Anti-MRSA agent 12 inhibits the methicillin-resistant S. aureus (MRSA) through inhibition of biofilm formation .
|
-
-
- HY-147882
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 6 (compound 3q6) is a potent anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) agent. Anti-MRSA agent 6 shows low cytoxicity for MCF-7, A549 cells .
|
-
-
- HY-122008
-
|
|
Bacterial
|
Infection
|
|
Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) arginine is a broad-spectrum antistaphylococcal agent. Levonadifloxacin arginine has antimicrobial activity against methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus and reduces phagocytosis of MRSA and MSSA strains by monocytic THP-1.
|
-
-
- HY-156289
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 8 (Compound 7g) is a DAPG derivative with strong antibacterial activity. Anti-MRSA agent 8 assertes its activity by targeting bacterial cell membranes. Anti-MRSA agent 8 can be used for the research of methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
-
- HY-N14118
-
|
|
Bacterial
|
Infection
|
|
Chloropolysporin B has strong activity of anti-Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and enterococcus bacteria .
|
-
-
- HY-N13885
-
|
|
Antibiotic
Bacterial
Parasite
|
Infection
|
|
Amythiamicin A is an antimicrobial antibiotic against Gram-positive bacteria (including methicillin-resistant Staphylococcus aureus (MRSA)) and activity against Plasmodium falciparum .
|
-
-
- HY-N14119
-
|
|
Bacterial
|
Infection
|
|
Chloropolysporin C has strong activity of anti-Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and enterococcus bacteria .
|
-
-
- HY-N3515
-
|
|
Bacterial
|
Infection
|
|
Multicaulisin, a new Diels-Alder type adduct from Morus multicaulis roots, potently effects against Staphylococcus aureus (MRSA) isolates. Multicaulisin is an antibacterial agent and has the potential for MRSA infections research .
|
-
-
- HY-146428
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 4 (compound 7a) is a potent and selective growth inhibitor of Gram-positive Methicillin-resistant Staphylococcus aureus (MRSA), with MIC ≤ 0.26 µM. Anti-MRSA agent 4 exhibits no cytotoxic and no hemolytic activity in HEK293 cells .
|
-
-
- HY-N6908R
-
|
|
Reference Standards
Bacterial
|
Infection
Inflammation/Immunology
Cancer
|
|
Continentalic acid (Standard) is the analytical standard of Continentalic acid. This product is intended for research and analytical applications. Continentalic acid from Aralia continentalis has minimum inhibitory concentrations (MICs) of approximately 8-16 μg/mL against S. aureus, including the Methicillin (HY-121544) susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus (MRSA) standard strains .
|
-
-
- HY-14926B
-
|
(S)-(-)-Nadifloxacin arginine; WCK 771 arginine
|
Bacterial
|
Infection
|
|
Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) arginine is a broad-spectrum antistaphylococcal agent. Levonadifloxacin arginine has antimicrobial activity against methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus and reduces phagocytosis of MRSA and MSSA strains by monocytic THP-1 cells .
|
-
-
- HY-N13881
-
|
|
Antibiotic
Bacterial
Parasite
|
Infection
|
|
Amythiamicin C is an antimicrobial antibiotic against Gram-positive bacteria (including methicillin-resistant Staphylococcus aureus (MRSA)) and activity against Plasmodium falciparum .
|
-
-
- HY-161893
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 15 (Compound 9o10) exhibits antibacterial activity, that inhibits methicillin-resistant Staphylococcus aureus (MRSA) with a MIC of 0.0625 μg/mL. Anti-MRSA agent 15 exhibits low hemolysis and low cytotoxicity. Anti-MRSA agent 15 exhibits anti-infective in mice .
|
-
-
- HY-14737
-
|
TAK-599; PPI0903
|
Bacterial
Antibiotic
|
Infection
|
|
Ceftaroline fosamil (TAK-599), a cephalosporin derivative, is an N-phosphono proagent of anti-methicillin-resistant Staphylococcus aureus (MRSA) T-91825. Ceftaroline fosamil can be used for the research of MRSA infection .
|
-
-
- HY-156198
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Bottromycin A2 is a natural antibiotic. Bottromycin A2 is active against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) .
|
-
-
- HY-157141
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 163 (compound 1), a hydroxyquinoline derivative, is a potent bacterial inhibitor. Antibacterial agent 163 inhibits methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
-
- HY-157142
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 165 (compound 3), a hydroxyquinoline derivative, is a potent bacterial inhibitor. Antibacterial agent 165 inhibits methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
-
- HY-17626C
-
|
(R)-WCK-2349
|
Antibiotic
|
Others
|
|
(R)-Alalevonadifloxacin mesylate is an isomer of Alalevonadifloxacin mesylate (HY-17626B). Alalevonadifloxacin mesylate is a oraly active anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotic .
|
-
-
- HY-N14470
-
|
|
Bacterial
|
Infection
|
|
Kigamicin A shows activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) with MICs of 0.025-0.78 μg/mL .
|
-
-
- HY-168873
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 23 (compound 11) is a potent anti-methicillin-resistant Staphylococcus aureus agent. Anti-MRSA agent 23 shows antibacterial and antibiofilm activities. Anti-MRSA agent 23 accelerates the reconstruction and healing of MRSA-infected cutaneous wounds by decreasing bacterial loads, attenuating inflammation, and promoting angiogenesis .
|
-
-
- HY-174273
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 280 (Compound 7af) is an antibacterial agent targeting methicillin-resistant and vancomycin-resistant Staphylococcus aureus (MRSA, VRSA). Antibacterial agent 280 is promising for research of is promising for research of S. aureus infections .
|
-
-
- HY-115965R
-
|
|
Reference Standards
Bacterial
Antibiotic
|
Infection
|
|
VP-4604 (Standard) is the analytical standard of VP-4604. This product is intended for research and analytical applications. VP-4604 is a potent anti-methicillin-resistant Staphylococcus aureus (MRSA) agent. VP-4604 exhibits significant microbial growth inhibition toward Staphylococcus aureus (ATCC 43300) with MIC of 4-8 μg/mL. VP-4604 inhibits the growth of methicillin‐resistant Staphylococcus aureus with growth inhibition >95%[1].
|
-
-
- HY-N14476
-
|
|
Bacterial
|
Infection
|
|
Kigamicin B shows activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) with MICs of 0.025-0.78 μg/mL .
|
-
-
- HY-174459
-
|
|
Bacterial
Penicillin-binding protein (PBP)
|
Infection
|
|
Anti-MRSA agent 31 (Compound 6) is an anti-methicillin-resistant Staphylococcus aureus (MRSA) agent with a MIC of 97 μg/mL and a MBC of 781.25 μg/mL. Anti-MRSA agent 31 has a potent antibacterial activity and a strong Binding Protein 2a (PBP2a) inhibitory activity .
|
-
-
- HY-N10834
-
|
|
Bacterial
|
Infection
|
|
(6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol is an antibacterial compound. (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol can be isolated from the roots of Atractylodes japonica. (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol has anti-methicillin-resistant Staphylococcus aureus (MRSA) activity with MIC values of 4-32 μg/mL. (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol can be used for the research of bacterial infection . (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-146458
-
|
|
Bacterial
Cytochrome P450
|
Infection
|
|
Antibacterial agent 102 (compound 32) possesses potent in vitro and in vivo antibacterial activity, with MICs < 0.5 μg/mL in Staphylococcus aureus (S. aureus). Antibacterial agent 102 also moderately inhibits CYP3A4 with an IC50 value of 6.148 μM. Antibacterial agent 102 can reduce Methicillin-resistant Staphylococcus aureus (MRSA) load in thigh infected mice .
|
-
-
- HY-116168
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Aldecalmycin is an antibiotic showing antimicrobial activities against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) with MICs values of 6.25-25 μg/mL .
|
-
-
- HY-N2058
-
|
|
Bacterial
Apoptosis
|
Infection
Cancer
|
|
Neogambogic acid, an active ingredient in garcinia, induces apoptosis and has anticancer effect. Neogambogic acid has significant inhibitory activity toward methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
-
- HY-14738
-
|
TAK-599 free acid; PPI0903 free acid
|
Bacterial
Antibiotic
|
Infection
|
|
Ceftaroline fosamil (inner) (TAK-599 free acid), a cephalosporin derivative, is an N-phosphono proagent of anti-methicillin-resistant Staphylococcus aureus (MRSA) T-91825. Ceftaroline fosamil (inner) can be used for the research of MRSA infection .
|
-
-
- HY-144822
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 2 (compound 14) has highly inhibitory activity against Methicillin-resistant Staphylococcus aureus (MRSA) with MIC of 0.098 μg/ml, and relatively low cytotoxicity in normal cells. Anti-MRSA agent 2 has strong ability to destroy bacterial membrane and bind to genomic DNA .
|
-
-
- HY-173225
-
|
|
Bacterial
|
Infection
|
|
MRSA/VRE-IN-1 (Compound 3e) is an inhibitor against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). The MIC/MBC of MRSA/VRE-IN-1 against VRE is 3.6/7.3 µM, and against MRSA is 7.3/14.6 µM. MRSA/VRE-IN-1 can be used in the research of the anti-infection field .
|
-
-
- HY-Z8025
-
|
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
Deprodone is an active compound. Deprodone inhibits key processes such as bacterial cell wall synthesis by interacting with the hydrolase and transferase proteins of methicillin-resistant Staphylococcus aureus (MRSA). Deprodone is used in research on anti-MRSA infection, inflammatory skin disorders, bowel disease, and fatty acid metabolism disorders .
|
-
-
- HY-124199
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Cephalochromin is an antibiotic and an inhibitor for bacterial fatty acid synthase (FabI). Cephalochromin inhibits FabI of Staphylococcus aureus and Escherichia coli with IC50 of 1.9 and 1.8 μM. Cephalochromin inhibits gram-positive methicillin-resistant S. aureus (MRSA) and quinolone-resistant S. aureus (QRSA), with MIC of 2-8 µg/mL .
|
-
- HY-173240
-
|
|
Bacterial
|
Infection
|
|
IPMCL-28b is an antibacterial agent targeting the bacterial cell membrane. Its minimum inhibitory concentration (MIC) against Staphylococcus aureus ATCC 25923 is 1.56 μg/mL, and the MIC against methicillin-resistant Staphylococcus aureus (MRSA) is 6.25 μg/mL. IPMCL-28b is expected to be used in the research of the anti-infection field .
|
-
- HY-148576
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Antibacterial agent 136 (compound 3) is an antibiotic of oxadiazolones. Antibacterial agent 136 have high antibacterial potency against Staphylococcus aureus (MRSA) with a MIC50 value of 0.8 μM .
|
-
- HY-173197
-
|
|
Bacterial
|
Infection
|
|
PBP4-IN-1 (Compound 1) is an inhibitor of penicillin-binding protein 4 (PBP4) of Staphylococcus aureus. PBP4-IN-1 enhances the inhibitory activity of antibiotics against PBP2a-mediated methicillin-resistant Staphylococcus aureus (MRSA) by inhibiting the function of PBP4. PBP4-IN-1 can be used for the study of osteomyelitis caused by Staphylococcus aureus and for the study of reversing PBP4-mediated resistance to β-lactam antibiotics.
|
-
- HY-146403
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 98 (compound g37) is a potent and orally active antibacterial agent. Antibacterial agent 98 inhibits the ATPase activity of Gyrase B and impairs Staphylococcus aureus (S. aureus ) DNA supercoiling. Antibacterial agent 98 shows antibacterial activity and not induce resistance development of MRSA (methicillin-resistant S. aureus) .
|
-
- HY-144823
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 3 (compound 18) has highly inhibitory activity against Methicillin-resistant Staphylococcus aureus (MRSA) with MIC of 0.098 μg/ml, and low cytotoxicity in normal cells. Anti-MRSA agent 3 has relatively strong ability to destroy bacterial cell wall and membrane, high binding affinity to bacterial genomic DNA .
|
-
- HY-N5184
-
|
Nocathiacine III
|
Bacterial
|
Infection
|
|
Nocathiacin III (Nocathiacine III) is highly resistant to Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP) and multidrug resistant Enterococcus faecalis (MREF) .
|
-
- HY-N5195
-
|
Nocathiacine II
|
Bacterial
|
Infection
|
|
Nocathiacin II (Nocathiacine II) is highly resistant to Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP) and multidrug resistant Enterococcus faecalis (MREF) .
|
-
- HY-129487
-
|
|
Bacterial
|
Infection
|
|
(E/Z)-MC4 is an enantiomer of the antibacterial agent MC4, which has antibacterial activity against a group of Staphylococcus aureus strains including MRSA, and has no significant toxicity to mammalian cells .
|
-
- HY-N5196
-
|
Nocathiacine I
|
Bacterial
|
Infection
|
|
Nocathiacin I (Nocathiacine I) is highly resistant to Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP) and multidrug resistant Enterococcus faecalis (MREF) .
|
-
- HY-N15451
-
|
|
Pyruvate Kinase
|
Infection
|
|
Deoxytopsentin is a compound that can be found in marine sponges. It is an inhibitor of pyruvate kinase (PK) in methicillin-resistant Staphylococcus aureus (MRSA), with an IC50 value of 240 nM. Deoxytopsentin can be used in research in the field of anti-infection .
|
-
- HY-14926A
-
|
(S)-(-)-Nadifloxacin (arginine) hydrate; WCK-771A (arginine) hydrate
|
Antibiotic
Bacterial
|
Infection
|
|
Levonadifloxacin (arginine) hydrate is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin (arginine) hydrate shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes .
|
-
- HY-14926
-
|
(S)-(-)-Nadifloxacin; WCK 771
|
Antibiotic
Bacterial
|
Infection
|
|
Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes .
|
-
- HY-W112166A
-
|
|
Bacterial
|
Infection
|
|
4,4'-Dicyanostilbene (compound 43) is a potent antimalarial agent against the Dd2 strain, with an EC50 of 27 nM. 4,4'-Dicyanostilbene exhibits in vivo efficacy against methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
- HY-173080
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 267 (Compound h19) is a pleuromutilin derivative with a potent antibacterial activity on Gram-positive bacteria. Antibacterial agent 267 shows an antibacterial activity in methicillin-resistant Staphylococcus aureus (MRSA)-infected mouse models .
|
-
- HY-162564
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Antibacterial agent 221 (compound 3k) is a potent inhibitor of Gram-positive Methicillin-resistant Staphylococcus aureus (MRSA). Antibacterial agent 221 shows significant cytotoxicity against human LO2 and HepG2 cells .
|
-
- HY-W024297
-
|
|
Bacterial
|
Infection
|
|
VP-4509, an anti-methicillin‐resistant Staphylococcus aureus (MRSA) agent, with the MIC of 49.3 µM. VP-4509 also possesses high antibacterial activity towards gram-negative bacteria P. aeruginosa .
|
-
- HY-125424
-
|
|
Bacterial
|
Inflammation/Immunology
|
|
AM8191 is an orally active bactericidal and selectively inhibits DNA synthesis and Staphylococcus aureus gyrase (IC50=1.02 μM) and topo IV (IC50=10.4 μM). AM8191 inhibits S. aureus MSSA (MIC=0.02 μg/mL) and S. aureus MRSA (MIC=0.06 μg/mL) .
|
-
- HY-143326
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 83 (compound 17h) displays potent antibacterial activity against various vancomycin-resistant Enterococcus faecalis (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). Antibacterial agent 83 can significantly reduce the biofilm formation of MRSA and exhibited promising selectivity. Antibacterial agent 83 is metabolically stable in human liver microsomes .
|
-
- HY-14737R
-
|
TAK-599 (Standard); PPI0903 (Standard)
|
Reference Standards
Bacterial
Antibiotic
|
Infection
|
|
Ceftaroline fosamil (Standard) is the analytical standard of Ceftaroline fosamil. This product is intended for research and analytical applications. Ceftaroline fosamil (TAK-599), a cephalosporin derivative, is an N-phosphono proagent of anti-methicillin-resistant Staphylococcus aureus (MRSA) T-91825. Ceftaroline fosamil can be used for the research of MRSA infection[1][2][3].
|
-
- HY-A0097
-
|
Antibiotic MDL-507; MDL-507
|
Bacterial
Antibiotic
|
Infection
|
|
Teicoplanin is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .
|
-
- HY-A0097A
-
|
Antibiotic MDL-507 sodium; MDL-507 sodium
|
Antibiotic
HIV
SARS-CoV
|
Infection
|
|
Teicoplanin sodium is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin sodium shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .
|
-
- HY-N14955
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
3-O-α-D-Forosaminyl-(+)-griseusin is a memberof naphthoquinone antibiotic. 3-O-α-D-Forosaminyl-(+)-griseusin is active against Gram-positive bacteria including methicillin-resistant strain of Staphylococcus aureus (MRSA) .
|
-
- HY-161018
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
CF3–K11 is a stable antibiotic with antibacterial activity. CF3–K11 has strong antibacterial activity against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA).
|
-
- HY-N10765
-
|
|
Bacterial
|
Inflammation/Immunology
Cancer
|
|
Salvinolone is active against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Salvinolone shows cytotoxic activity with an IC50 of 47.6 μM against the HL-60 tumor cell line for 72 h .
|
-
- HY-N15019
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Glycothiohexide α is a peptide antibiotic. Glycothiohexide α has strong activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococcus (VREF), MIC values of 0.03-0.06 μg/mL .
|
-
- HY-173478
-
|
|
Topoisomerase
Bacterial
Antibiotic
|
Infection
|
|
OSUAB-0284 is a bacterial topoisomerase inhibitor. OSUAB-0284 has significant anti-staphylococcal activity, especially against methicillin-resistant Staphylococcus aureus (MRSA). OSUAB-0284 exerts its antibacterial effect by inhibiting bacterial topoisomerase. OSUAB-0284 can be used to study infections caused by drug-resistant bacteria such as MRSA .
|
-
- HY-172826
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 26 is a potent anti-MRSA agent with MIC <0.015 μg/mL. Anti-MRSA agent 26 has superior activity against a broad range of Gram-positive pathogens and shows no cytotoxicity in three mammalian cell lines (Caco-2, DU-145 and MDCKII MDR1 cells) at 10 μM. Anti-MRSA agent 26 has a robust TAP pharmacophore and an excellent antibacterial activity in Staphylococcus aureus skin infection mice model .
|
-
- HY-N14171
-
|
|
Bacterial
Fungal
|
Infection
|
|
Epicorazine A has activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococcus (VRE), MICs of 12.5-25 μg/mL. Epicorazine A also has effect on Candida albicans with a MIC of 25 μg/mL .
|
-
- HY-127155
-
|
|
Bacterial
Antibiotic
|
Infection
Cancer
|
|
Kigamicin C is an anti-tumor antibiotic that selectively kills pancreatic cancer PANC-1 cells only in nutrient-poor conditions. Kigamicin C has antimicrobial activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
- HY-141648
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 219 (Compound 2/75c) exhibits antibacterial activity by targeting cell wall biosynthesis. Antibacterial agent 219 inhibits methicillin-resistant Staphylococcus aureus (MRSA) strains (MIC=0.5-32 µg/mL), Enterococcus faecium (MIC=2 µg/mL) and S. aureus (MIC=2 µg/mL) .
|
-
- HY-170398
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
ZG297 is an agonist for Staphylococcus aureus ClpP (SaClpP ) with an EC50 of 0.26 μM. ZG297 degrades SaFtsZ, inhibits the bacterial cell division, thereby exhibiting antistaphylococcal activity, that inhibits S. aureus 8325-4 strains and MRSA strains with MIC of 0.063-256 μg/mL. ZG297 exhibits anti-infectious efficacy in mouse models .
|
-
- HY-173318
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 25 (Compound 10c) is an antibacterial agent with a MIC of 0.25 μg/mL against methicillin-resistant Staphylococcus aureus (MRSA). Anti-MRSA agent 25 exerts its antibacterial activity by inhibiting biofilm formation, disrupting the cell wall (interacting with peptidoglycan and lipoteichoic acids), acting on the cell membrane (causing depolarization, increasing permeability, and disrupting integrity), reducing metabolic activity, interfering with cellular redox homeostasis, and binding to DNA. Anti-MRSA agent 25 is expected to be used in the research of the anti-infection field .
|
-
- HY-163615
-
|
|
Bacterial
|
Infection
|
|
Antimicrobial agent-32 (Compound 4g) is an antimicrobial agent that exhibits significant activity against various bacteria, including Staphylococcus aureus, Bacillus subtilis, Bacillus cereus (MIC=1000 µg/mL), Klebsiella pneumonia, and Staphylococcus aureus (MRSA) (MIC=500 µg/mL), as well as Escherichia coli (MIC=250 µg/mL). Additionally, Antimicrobial agent-32 inhibits the proliferation of MCF-7, HCT-116, and HepG-2 cells, demonstrating anticancer activity .
|
-
- HY-128384
-
|
|
Bacterial
|
Infection
|
|
Benzyldodecyldimethylammonium chloride dihydrate is a quaternary ammonium compound (QAC) and can be used as a biocide to target antibiotic-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant (MDR) P. aeruginosa et. al. Benzyldodecyldimethylammonium chloride dihydrate, an antimicrobial agent, bacteriostatic or bactericidal properties depending on the concentration.
|
-
- HY-N14172
-
|
|
Bacterial
Fungal
|
Infection
|
|
Epicorazine B has activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococcus (VRE), MICs of 12.5-25 μg/mL. Epicorazine B also has effect on Candida albicans with a MIC of 25 μg/mL .
|
-
- HY-A0279
-
|
Pristinamycine
|
Bacterial
Antibiotic
|
Infection
|
|
Pristinamycin, produced by Streptomyces pristinaespiralis, is an orally active streptogramin-like antibiotic consisting of two chemically unrelated components: Pristinamycin I (PI) and Pristinamycin II (PII). Pristinamycin is highly active against many antibiotic-resistant pathogens, particularly Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant S. aureus (VRSA) and Enterococcus faecium (VREF) .
|
-
- HY-14926R
-
|
(S)-(-)-Nadifloxacin (Standard); WCK 771 (Standard)
|
Reference Standards
Antibiotic
Bacterial
|
Infection
|
|
Levonadifloxacin (Standard) is the analytical standard of Levonadifloxacin. This product is intended for research and analytical applications. Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes[1].
|
-
- HY-158402
-
|
|
Bacterial
Fungal
|
Infection
Inflammation/Immunology
|
|
Anti-inflammatory agent 84 (Compound 4D) is a derivative of Coumarin (HY-N0709) with antimicrobial and anti-inflammatory activities. Anti-inflammatory agent 84 inhibits E. coli, Candida albicans, Staphylococcus aureus and methicillin-resistant S. aureus (MRSA), with MIC of 312, 156, 19 and 316 μg/mL, respectively. Anti-inflammatory agent 84 inhibits biofilm formation of S. aureus, E. coli and MRSA, with IC50 of 185, 321 and 99 μM, respectively. Anti-inflammatory agent 84 inhibits nitric oxide production in Lipopolysaccharide (HY-D1056)-stimulated RAW264.7 macrophage cell .
|
-
- HY-121000
-
|
Ingramycin
|
Antibiotic
Bacterial
|
Infection
|
|
Albocycline (Ingramycin) is a macrolide antibiotic, which exhibits antibacterial activities against methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin (HY-B0671)-intermediate (VISA), and Vancomycin (HY-B0671)-resistant S. aureus (VRSA) strains with MICs ranging from 0.5 to 1.0 μg/mL. Albocycline exhibits no toxicity to human cells at concentration of ≤64 μg/mL .
|
-
- HY-14849
-
|
Razupenem; SM 216601; SMP 601
|
Antibiotic
Bacterial
|
Others
|
|
PTZ601 (SMP 601) is an antibiotic, which inhibits the gram-positive bacteria, including the Vancomycin (HY-B0671)-resistant Enterococcus faecium (VREF) and Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA). PTZ601 exhibits antimicrobial activity in infected mouse models .
|
-
- HY-N2245
-
|
|
CD74
|
Cancer
|
|
Schisandrone, a 4-aryltetralone lignan, is isolated from the dried fruits of Schisandra sphenanthera . Schisandrone is an alpha-hemolysin (Hla) inhibitor that downregulates the transcript levels of hla, agrA and RNAIII. Hla is an integral virulence determinant in Staphylococcus aureus that determines pathogenicity. Schisandrone is a potent inhibitor against MRSA pneumonia .
|
-
- HY-N14530
-
|
|
Bacterial
|
Infection
Cancer
|
|
Cremeomycin has anti-Gram-positive bacteria activity including methicillin-resistant Staphylococcus aureus (MRSA), MIC is 0.2-0.39 μg/mL. Cremeomycin shows cytotoxicity to mouse tumor cell lines P388, L1210, IMC, S180, B16 and SS3 in vitro .
|
-
- HY-N14144
-
|
|
Bacterial
|
Infection
Cancer
|
|
Cremimycin has anti-Gram-positive bacteria activity including methicillin-resistant Staphylococcus aureus (MRSA), MIC is 0.2-0.39 μg/mL. Cremimycin shows cytotoxicity to mouse tumor cell lines P388, L1210, IMC, S180, B16 and SS3 in vitro .
|
-
- HY-156122
-
|
|
Dihydrofolate reductase (DHFR)
Bacterial
|
Infection
|
|
DHFR-IN-8 (compound 6r) is a dihydrofolate reductase (DHFR) inhibitor that affects purine and thymidylate biosynthesis in cell proliferation and growth. DHFR-IN-8 inhibits methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 (IC50=15.6 ng/mL) in mouse models of systemic infection and thigh infection .
|
-
- HY-168486
-
|
|
Bacterial
|
Infection
|
|
Biotin protein ligase-IN-1 (Compound Bio-9) is an inhibitor of biotin protein ligase (BPL) with a Kd value of 7 nM. Biotin protein ligase-IN-1 exhibits antibacterial activity, with MIC values of 0.2 and 20 μM against Staphylococcus aureus (including MRSA and MSSA) and Mycobacterium tuberculosis, respectively .
|
-
- HY-155682
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 150 (compound 5g) is an antibacterial agent with potent antibacterial activity against both Gram-positive bacteria and Gram-negative bacteria (MIC values ranging from 1-32 μg/mL). Antibacterial agent 150 can increase survival rate of MRSA (Methicillin-resistant Staphylococcus aureus)-infected mice .
|
-
- HY-N14484
-
|
|
Bacterial
|
Infection
Cancer
|
|
Kigamicin D shows activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) with MICs of 0.025-0.78 μg/mL. Kigamicin D also shows effect against L-1210 LB32T and other genera tumor cells with IC50 of 1 μg/mL .
|
-
- HY-147755
-
|
|
Bacterial
|
Infection
|
|
C16-K-cBB1 is a potent and selective antimicrobial agent for MRSA (Methicillin resistant Staphylococcus aureus), with a MIC of 1 µg/mL. C16-K-cBB1 has very good selectivity, as it has weak hemolytic activity. C16-K-cBB1 is able to kill MRSA cells in a matter of 120 min at a concentration of 12.5 μg/mL .
|
-
- HY-P10539
-
|
|
Bacterial
|
Infection
|
|
Hp1404 is a novel cationic antimicrobial peptide. Hp1404 has specific inhibitory activity against Gram-positive bacteria, including Staphylococcus aureus (MRSA) resistant to Laburnetin (HY-N7382). Hp1404 has antimicrobial activity, low toxicity, and is not prone to drug resistance, and can be used in the research of antimicrobial agents .
|
-
- HY-112959
-
|
TD-6424
|
Antibiotic
Bacterial
|
Infection
|
|
Telavancin (TD-6424) is a semisynthetic lipoglycopeptide vancomycin-derivative, is a novel antimicrobial agent developed by Theravance for overcoming resistant Gram-positive bacterial infections, specifically methicillin-resistant Staphylococcus aureus (MRSA). Telavancin disrupts cell membrane integrity, can be used for research of complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria .
|
-
- HY-174158
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 270 (Compound 3e) is an antibacterial agent that acts on bacterial membrane components phosphatidylglycerol (PG), cardiolipin (CL), and bacterial DNA. Antibacterial agent 270 disrupts bacterial membrane structure and binds to DNA to interfere with genetic information transmission. Antibacterial agent 270 is promising for research of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
- HY-N11879
-
|
|
Bacterial
Antibiotic
|
Others
|
|
6-C-Methylquercetin-3,4'-dimethyl etheris a flavonol derivative isolated from the leaves of Bauhinia thonningii Schum. 6-C-Methylquercetin-3,4'-dimethyl ether has antibacterial activity against Gram-negative multidrug-resistant bacteria and against methicillin-resistant Staphylococcus aureus (MRSA) strains .
|
-
- HY-157044
-
|
|
Bacterial
|
Infection
Cancer
|
|
Antibacterial agent 162 trifluoromethanesulfonate (compound 7) is an antibacterial agent that exhibits potent inhibitory activity against Staphylococcus aureus, including MRSA. Antibacterial agent 162 trifluoromethanesulfonate is also an anticancer agent and exhibits antiproliferative activity against colon cancer and non-small cell lung cancer cells. Antibacterial agent 162 trifluoromethanesulfonate can be used in anticancer and antibacterial research .
|
-
- HY-N15272
-
-
- HY-121300
-
|
(-)-TAN2162
|
Antibiotic
Bacterial
Endothelin Receptor
CGRP Receptor
|
Infection
Cancer
|
|
Kendomycin ((−)-TAN 2162) is a polyketide antibiotic with remarkable antibacterial and cancer cells cytotoxic activities. Kendomycin tends to be bacteriostatic rather than bactericidal and inhibits the growth of the methicillin-resistant Staphylococcus aureus (MRSA) strain COL at a low concentration (MIC of 5 μg/mL). Kendomycin is a potent antagonist of the endothelin receptor and a calcitonin receptor agonist which plays its role as an anti-osteoporotic agent .
|
-
- HY-13067
-
Celastrol
Maximum Cited Publications
48 Publications Verification
Tripterine; Tripterin
|
Proteasome
Autophagy
Mitophagy
Apoptosis
Endogenous Metabolite
Antibiotic
Bacterial
|
Infection
Inflammation/Immunology
Cancer
|
|
Celastrol (Tripterine;Tripterin) is a proteasome inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. In addition, Celastrol is also an antibiotic with potent antimicrobial activity against standard and clinical methicillin-resistant Staphylococcus aureus (MRSA) strains, inducing oxidative stress and inhibiting DNA synthesis by binding to P5CDH .
|
-
- HY-W112166
-
|
|
Parasite
Drug Isomer
|
Infection
|
|
(E/Z)-4,4'-Dicyanostilbene is the isomer of 4,4'-Dicyanostilbene (HY-W112166A), and can be used as an experimental control. 4,4'-Dicyanostilbene (compound 43) is a potent antimalarial agent against the Dd2 strain, with an EC50 of 27 nM. 4,4'-Dicyanostilbene exhibits in vivo efficacy against methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
- HY-B1924
-
|
N-Demethylvancomycin monohydrochloride; NVCM monohydrochloride
|
Bacterial
Antibiotic
|
Infection
|
|
Norvancomycin hydrochloride is a cell wall synthesis inhibitor targeting peptidoglycan precursors of Gram-positive bacteria and cannot pass the blood-brain barrier. Norvancomycin hydrochloride can competitively bind to peptidoglycan precursors, irreversibly inhibit bacterial cell wall synthesis, and exert antibacterial activity. Norvancomycin hydrochloride is mainly used in the study of Gram-positive bacterial infections, especially infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). Norvancomycin hydrochloride can also be incorporated into the bionic calcium phosphate coating of titanium implants to enhance antibacterial activity and inhibit postoperative orthopedic infections .
|
-
- HY-14737A
-
|
TAK-599 hydrate; PPI0903 hydrate
|
Antibiotic
Bacterial
|
Infection
|
|
Ceftaroline fosamil hydrate is a potent cephalosporin antibiotic. Ceftaroline fosamil hydrateshows broad-spectrum activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Streptococcus pneumoniae, and common Gram-negative organisms. Ceftaroline fosamil hydrate has anti-infective activity, and can be used for the research of complicated skin and skin structure infections (cSSSIs) and community-acquired bacterial pneumonia (CABP) .
|
-
- HY-W060074
-
|
|
Endogenous Metabolite
Bacterial
Tyrosinase
PERK
|
Infection
Endocrinology
|
|
1-Acetyl-β-carboline is a metabolite of Streptomyces kasugaensis and antibacterial agent. 1-Acetyl-β-carboline increases tyrosinase activity, reduces ERK phosphorylation. 1-Acetyl-β-carboline exhibits antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) strains with MICs ranging from 128 to 256 ug/mL. 1-Acetyl-β-carboline increases the melanin .
|
-
- HY-161935
-
|
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid (Compound 2) exhibits antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin enterococci (VRE). 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid interfers with the integrity and function of the bacterial cell membrane, and affects metabolism in MRSA. 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid exhibits anti-inflammatory and anti-infective efficacy, and promotes angiogenesis in mice .
|
-
- HY-147546
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 107 (compound 14) is a potent antibacterial agent. Antibacterial agent 107 shows potent antibacterial activity against Gram-positive bacteria, with a MIC of 1.56 μg/mL (MRSA). Antibacterial agent 107 exhibits low hemolytic activity, high membrane selectivity, and rapid bactericidal activity. Antibacterial agent 107 shows effective in vivo efficacy in the murine model of bacterial keratitis caused by Staphylococcus aureus ATCC29213 .
|
-
- HY-174333
-
|
|
Bacterial
Cytochrome P450
|
Infection
Cardiovascular Disease
|
|
CYP1A1-IN-1 (Compound 47) is a small-molecule cytochrome P4501A1 (CYP1A1) inhibitor. CYP1A1-IN-1 reduces the bacterial loads of methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii by enhancing macrophage phagocytosis. CYP1A1-IN-1 is promising for research of sepsis caused by multidrug-resistant (MDR) bacteria .
|
-
- HY-163463
-
|
|
Phosphatase
Fungal
HIV
Bacterial
|
Infection
Metabolic Disease
|
|
PTP1B-IN-25 (Compound 19) is a PTP1B inhibitor with remarkable antiviral, antibacterial, and antidiabetic activities. PTP1B-IN-25 has IC50 values of 0.37 μM, 8.6 μM, 3.7 μM, and 29 μM against PTP1B, HIV, α-Glucosidase, and methicillin-resistant Staphylococcus aureus (MRSA) respectively .
|
-
- HY-W013376
-
|
1-(Diphenylmethyl)piperazine; 1-Benzhydrylpiperazine
|
Antibiotic
Bacterial
Penicillin-binding protein (PBP)
|
Infection
Cancer
|
|
Norcyclizine is a piperazine compound that can be used for the synthesis of antimicrobial agents. 1-Benzhydrylpiperazine derivatives have been found to enhance the antibacterial activity of β-lactam antibiotics (Oxacillin, HY-B0925A) against Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA). This enhancement is likely achieved by inhibiting the allosteric site of PBP2a. Additionally, 1-Benzhydrylpiperazine can also serve as a pharmacological scaffold for the synthesis of anticancer agents .
|
-
- HY-16764A
-
|
JNJ-Q2 hydrochloride
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
Acorafloxacin hydrochloride (JNJ-Q2 hydrochloride) is a broad-spectrum fluoroquinolone anti-bacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia .
Acorafloxacin hydrochloride (Avarofloxacin ) is an aminoethylidenylpiperidine fluoroquinolone that demonstrates antibacterial effect against numerous Gram-positive bacteria with a mean 0.12 mg/L MIC90 value .
Acorafloxacin hydrochloride (JNJ-Q2) has potential for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections .
|
-
- HY-P2358
-
|
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
|
PSMα3 is a peptide for manipulating DCs to become tolerogenic for DC vaccination strategies. PSMα3 penetrates and modulates human monocyte-derived DCs by altering the TLR2- or TLR4-induced maturation, inhibiting pro- and anti-inflammatory cytokine production and reducing antigen uptake. PSMα3 is an important toxin released by the most virulent strains of methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
- HY-P2358A
-
|
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
|
PSMα3 TFA is a peptide for manipulating DCs to become tolerogenic for DC vaccination strategies. PSMα3 TFA penetrates and modulates human monocyte-derived DCs by altering the TLR2- or TLR4-induced maturation, inhibiting pro- and anti-inflammatory cytokine production and reducing antigen uptake. PSMα3 TFA is an important toxin released by the most virulent strains of methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
- HY-16764
-
|
JNJ-Q2
|
Bacterial
Antibiotic
|
Infection
Inflammation/Immunology
|
|
Avarofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial agent being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia with oral activity. Avarofloxacin (JNJ-Q2) is an aminoethylidenylpiperidine fluoroquinolone that demonstrates antibacterial effect against numerous Gram-positive bacteria with a mean 0.12 mg/L MIC90 value. Avarofloxacin (JNJ-Q2) has potential for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections .
|
-
- HY-146460
-
|
|
Reactive Oxygen Species (ROS)
|
Infection
|
|
Antimicrobial agent-2 (compound V-a) is a broad-spectrum antimicrobial agent, possessing inhibitory activity against various Gram-positive and -negative bacteria. Antimicrobial agent-2 has excellent inhibitory effect on Methicillin-resistant Staphylococcus aureus (MRSA) with a MIC of 1 μg/mL. Antimicrobial agent-2 can effectively damage the membrane and lead to the leakage of protein, also can induce the generation of ROS. Antimicrobial agent-2 exhibits low toxicity, no obvious resistance and good bioavailability .
|
-
- HY-162761
-
|
|
Bacterial
COX
|
Inflammation/Immunology
|
|
COX-1/2-IN-9 (Compound 3n) is a potent and selective inhibitor of COX-1/2, with IC50 values of 0.031 µM and 0.01 µM, respectively. COX-1/2-IN-9 possesses both antibacterial and anti-inflammatory activities, effectively inhibiting MRSA 1478 (MIC=50 μg/mL) and multidrug-resistant S. lentus (MIC=50 μg/mL). COX-1/2-IN-9 holds significant potential to alleviate MRSA-induced pneumonia in immunocompromised states .
|
-
- HY-13067G
-
|
Tripterine; Tripterin
|
Endogenous Metabolite
Proteasome
Antibiotic
Apoptosis
Bacterial
Autophagy
Mitophagy
|
Infection
Inflammation/Immunology
Cancer
|
|
Celastrol (GMP) (Tripterine (GMP)) is Celastrol (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Celastrol (Tripterine;Tripterin) is a proteasome inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. In addition, Celastrol is also an antibiotic with potent antimicrobial activity against standard and clinical methicillin-resistant Staphylococcus aureus (MRSA) strains, inducing oxidative stress and inhibiting DNA synthesis by binding to P5CDH .
|
-
- HY-N10907
-
|
|
Bacterial
|
Infection
|
|
4(1H)-Quinolinone, 1-methyl-2-(5Z)-5-undecen-1-yl- (compound 2) is a quinolone alkaloid that can be isolated from Cnidium. 4(1H)-Quinolinone, 1-methyl-2-(5Z)-5-undecen-1-yl- has methicillin-resistant Staphylococcus aureus (MRSA) activity, with MIC values of 32 μg/mL (ATCC 33591) and 16 μM/mL (ATCC 25923), respectively .
|
-
- HY-170991
-
|
|
Bacterial
Reactive Oxygen Species (ROS)
|
Infection
|
|
C12-rrw-NH2 (Compound Lip7) is an antibacterial agent against gram-positive bacteria, especially against Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA). C12-rrw-NH2 induces bacterial death via depolarizing the bacterial cytoplasmic membrane, disrupting the integrity of the bacterial membrane, leading to leakage of nucleic acid and protein and promoting the generation of Reactive Oxygen Species. C12-rrw-NH2 is potential to be used for research of developing high-stability antimicrobial peptides .
|
-
- HY-156123
-
|
|
Dihydrofolate reductase (DHFR)
Bacterial
|
Infection
Cancer
|
|
DHFR-IN-9 (compound 8A) is a dihydrofolate reductase (DHFR) inhibitor that affects purine and thymidylate biosynthesis in cell proliferation and growth. DHFR-IN-9 inhibits methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 (IC50=0.25 μg/mL) and has anti-infective effects in mouse models of systemic infection and thigh infection caused by it (dose: 2.5 mg /kg, 5 mg/kg; ip). DHFR-IN-9 has stronger anticancer activity than paclitaxel (Y-B0015) in a mouse model of breast cancer (dose: 2.5 mg/kg; ip; once every 3 days) .
|
-
- HY-69174
-
|
|
Bacterial
|
|
|
1-Amino-2,5-anhydro-1-deoxy-D-mannitol is a potent antibacterial compound with antibacterial activity against a variety of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). The application potential of 1-Amino-2,5-anhydro-1-deoxy-D-mannitol lies in its ability to effectively combat common drug-resistant bacterial infections. 1-Amino-2,5-anhydro-1-deoxy-D-mannitol may become an emerging antibacterial agent in clinical inhibition.
|
-
- HY-N14145
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Collinone is a recombinant angular polyketide antibiotic. Collinone shows antibacterial activities for gram-positive bacterial. Collinone shows cytotoxicity .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-13067G
-
|
Tripterine (GMP); Tripterin (GMP)
|
Fluorescent Dye
|
|
Celastrol (GMP) (Tripterine (GMP)) is Celastrol (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Celastrol (Tripterine;Tripterin) is a proteasome inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. In addition, Celastrol is also an antibiotic with potent antimicrobial activity against standard and clinical methicillin-resistant Staphylococcus aureus (MRSA) strains, inducing oxidative stress and inhibiting DNA synthesis by binding to P5CDH .
|
| Cat. No. |
Product Name |
Type |
-
- HY-13067G
-
|
Tripterine (GMP); Tripterin (GMP)
|
Biochemical Assay Reagents
|
|
Celastrol (GMP) (Tripterine (GMP)) is Celastrol (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Celastrol (Tripterine;Tripterin) is a proteasome inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. In addition, Celastrol is also an antibiotic with potent antimicrobial activity against standard and clinical methicillin-resistant Staphylococcus aureus (MRSA) strains, inducing oxidative stress and inhibiting DNA synthesis by binding to P5CDH .
|
-
- HY-69174
-
|
|
Microbial Culture
|
|
1-Amino-2,5-anhydro-1-deoxy-D-mannitol is a potent antibacterial compound with antibacterial activity against a variety of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). The application potential of 1-Amino-2,5-anhydro-1-deoxy-D-mannitol lies in its ability to effectively combat common drug-resistant bacterial infections. 1-Amino-2,5-anhydro-1-deoxy-D-mannitol may become an emerging antibacterial agent in clinical inhibition.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P2358
-
|
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
|
PSMα3 is a peptide for manipulating DCs to become tolerogenic for DC vaccination strategies. PSMα3 penetrates and modulates human monocyte-derived DCs by altering the TLR2- or TLR4-induced maturation, inhibiting pro- and anti-inflammatory cytokine production and reducing antigen uptake. PSMα3 is an important toxin released by the most virulent strains of methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
- HY-P10539
-
|
|
Bacterial
|
Infection
|
|
Hp1404 is a novel cationic antimicrobial peptide. Hp1404 has specific inhibitory activity against Gram-positive bacteria, including Staphylococcus aureus (MRSA) resistant to Laburnetin (HY-N7382). Hp1404 has antimicrobial activity, low toxicity, and is not prone to drug resistance, and can be used in the research of antimicrobial agents .
|
-
- HY-P2358A
-
|
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
|
PSMα3 TFA is a peptide for manipulating DCs to become tolerogenic for DC vaccination strategies. PSMα3 TFA penetrates and modulates human monocyte-derived DCs by altering the TLR2- or TLR4-induced maturation, inhibiting pro- and anti-inflammatory cytokine production and reducing antigen uptake. PSMα3 TFA is an important toxin released by the most virulent strains of methicillin-resistant Staphylococcus aureus (MRSA) .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N6908
-
-
-
- HY-N3789
-
-
-
- HY-142124
-
-
-
- HY-N8186
-
-
-
- HY-N14125
-
-
-
- HY-N14118
-
-
-
- HY-N13885
-
-
-
- HY-N14119
-
-
-
- HY-N3515
-
-
-
- HY-N6908R
-
-
-
- HY-N13881
-
-
-
- HY-156198
-
-
-
- HY-N14470
-
-
-
- HY-N14476
-
-
-
- HY-N10834
-
|
|
Structural Classification
Natural Products
Source classification
Plants
Compositae
Erythrina sigmoidea Hua
|
Bacterial
|
|
(6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol is an antibacterial compound. (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol can be isolated from the roots of Atractylodes japonica. (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol has anti-methicillin-resistant Staphylococcus aureus (MRSA) activity with MIC values of 4-32 μg/mL. (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol can be used for the research of bacterial infection . (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-116168
-
-
-
- HY-N2058
-
-
-
- HY-124199
-
-
-
- HY-N5184
-
-
-
- HY-N5195
-
-
-
- HY-N5196
-
-
-
- HY-N15451
-
-
-
- HY-A0097
-
-
-
- HY-A0097A
-
-
-
- HY-N14955
-
-
-
- HY-N10765
-
-
-
- HY-N15019
-
-
-
- HY-N14171
-
-
-
- HY-127155
-
-
-
- HY-N14172
-
-
-
- HY-A0279
-
-
-
- HY-121000
-
|
Ingramycin
|
Structural Classification
Natural Products
Microorganisms
Source classification
|
Antibiotic
Bacterial
|
|
Albocycline (Ingramycin) is a macrolide antibiotic, which exhibits antibacterial activities against methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin (HY-B0671)-intermediate (VISA), and Vancomycin (HY-B0671)-resistant S. aureus (VRSA) strains with MICs ranging from 0.5 to 1.0 μg/mL. Albocycline exhibits no toxicity to human cells at concentration of ≤64 μg/mL .
|
-
-
- HY-N2245
-
-
-
- HY-N14530
-
-
-
- HY-N14144
-
-
-
- HY-N14484
-
-
-
- HY-N11879
-
-
-
- HY-N15272
-
-
-
- HY-13067
-
-
-
- HY-W060074
-
-
-
- HY-161935
-
-
-
- HY-P2358
-
-
-
- HY-N10907
-
-
-
- HY-N14145
-
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-174333
-
|
|
|
Alkynes
|
|
CYP1A1-IN-1 (Compound 47) is a small-molecule cytochrome P4501A1 (CYP1A1) inhibitor. CYP1A1-IN-1 reduces the bacterial loads of methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii by enhancing macrophage phagocytosis. CYP1A1-IN-1 is promising for research of sepsis caused by multidrug-resistant (MDR) bacteria .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
